Peptides
Body
Composition
Weight
Management
Recovery & Repair
Reproductive Health
& Tanning
Longevity
& Skin Care
Cognitive
Enhancement
Tesamorelin
Tirzepatide
TB-500
Kisspeptin
GHK-Cu
Selank
Ipamorelin
Semaglutide
BPC-157
Melanotan 2
Epithalon
Semax
CJC-1295
Retatrutide
NAD+
PT-141
DSIP
MOTS-C
5-Amino-1MQ
FRAG 176-191
Hexarelin
MK-677

Tesamorelin: The Complete Guide to Dosage, Benefits, and Research in 2024

Tesamorelin Dosage Chart | Quick Breakdown

Purpose Dosage Frequency Administration
HIV-related Lipodystrophy 1.4 mg (EGRIFTA SV) Once daily Subcutaneous injection
Research/Off-label use 1-2 mg Once daily Subcutaneous injection

2. What is Tesamorelin?

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. Key points:

  • 44 amino acid polypeptide

  • Modified N-terminal for improved stability and pharmacokinetics

  • FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy

  • Marketed under the brand name Egrifta/Egrifta SV

Table of Contents

3. Tesamorelin Mechanism of Action

Tesamorelin works through several mechanisms:

  1. Activates GHRH receptors in the pituitary gland

  2. Stimulates synthesis and release of growth hormone

  3. Increases production of insulin-like growth factor-1 (IGF-1)

  4. Promotes lipolysis and reduces visceral adiposity

  5. Influences glucose and lipid metabolism

4. Research Applications and Potential Benefits of Tesamorelin

Tesamorelin and HIV-related Lipodystrophy

  • Reduces excess abdominal fat

  • Improves body composition

Tesamorelin and Metabolic Health

  • Potential benefits for insulin resistance

  • Being studied for nonalcoholic fatty liver disease (NAFLD)

Tesamorelin and Athletic Performance

  • Potential for improved body composition

  • May support muscle growth and fat loss

Tesamorelin and Cognitive Function

  • Preliminary research suggests potential cognitive benefits

5. Tesamorelin Dosage Guide

Dosing Tesamorelin for HIV-related Lipodystrophy

  • FDA-approved dose: 1.4 mg of EGRIFTA SV once daily

Dosing Tesamorelin for Research/Off-label Use

  • Typical doses range from 1-2 mg once daily

6. How to Mix and Administer Tesamorelin

Reconstitution Procedure (for EGRIFTA SV)

  1. Use only the provided Sterile Water for Injection to reconstitute

  2. Reconstitute 1 vial with 0.5 mL of diluent

  3. Mix by rolling the vial gently for 30 seconds (do not shake)

  4. Use immediately after reconstitution

7. Tesamorelin Administration Methods

Tesamorelin is administered via subcutaneous injection only:

  • Inject into the abdomen

  • Rotate injection sites

  • Do not inject into scar tissue, bruises, or the navel

8. Tesamorelin Combinations and Interactions

  • May interact with insulin and oral hypoglycemics

  • Caution advised when used with cortisone, simvastatin, ritonavir, or prednisone

  • Potential interactions with other growth hormone-related compounds

9. Where to Buy Tesamorelin Online | 2024 Edition

Tesamorelin is a prescription medication and should only be obtained through licensed pharmacies with a valid prescription.

10. Is Tesamorelin Safe?

Generally considered safe but with some considerations:

  • Common side effects: injection site reactions, arthralgia, pain in extremities

  • Potential for glucose intolerance and insulin resistance

  • Contraindicated in patients with active malignancy

  • Caution advised in patients with diabetes or history of pituitary disorders

11. Is Tesamorelin Legal?

  • FDA-approved for HIV-related lipodystrophy in the United States

  • Prescription-only medication

  • Banned by WADA for competitive athletes (falls under S2.2.4 of the Prohibited List)

12. Tesamorelin Storage and Handling

  • Store lyophilized powder at room temperature (20°C to 25°C or 68°F to 77°F)

  • Protect from light

  • Use immediately after reconstitution

  • Do not freeze reconstituted solution

13. Frequently Asked Questions (FAQ)

How long does it take to see results with tesamorelin?

Results may vary, but changes in body composition are typically observed within 3-6 months of consistent use.

Can tesamorelin be used for bodybuilding?

While it may have potential benefits for body composition, tesamorelin is not approved for bodybuilding and is banned in competitive sports.

Is tesamorelin safe for long-term use?

Long-term safety data is limited. Continuous use should be monitored by a healthcare professional.

14. Tesamorelin Dosage | Final Verdict

Tesamorelin is a potent GHRH analogue with proven benefits for HIV-related lipodystrophy. Its potential extends to other areas of metabolic health, but more research is needed. The standard dose of 1.4 mg daily (EGRIFTA SV) is well-established for its approved use. Off-label or research applications may use different dosing protocols. As with any peptide hormone, use should be under medical supervision with careful consideration of individual health factors and potential risks.

15. References

  1. Drugs.com. (2024). Egrifta SV Dosage Guide.

  2. MedlinePlus. (2016). Tesamorelin Injection.

  3. Mayo Clinic. (2024). Tesamorelin (Subcutaneous Route) Side Effects.

  4. LIVV Natural. (n.d.). Tesamorelin: Benefits, Risks, and Ethics.

  5. LiverTox. (2018). Tesamorelin.

Disclaimer

Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.

Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.

Copyright 2024 - Peptide Researcher

Your access to Peptideresearcher.com is subject to our Terms of Use